Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia-Reference-Cited by-同舟云学术

Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia

Published:2016-12-20 Issue:2 Volume:8 Page:233-238
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Wood Michael R.¹²,Noetzel Meredith J.¹²,Melancon Bruce J.¹²,Poslusney Michael S.²,Nance Kellie D.²,Hurtado Miguel A.²,Luscombe Vincent B.¹²,Weiner Rebecca L.¹²,Rodriguez Alice L.¹²,Lamsal Atin¹²,Chang Sichen¹²,Bubser Michael¹²,Blobaum Anna L.¹²,Engers Darren W.¹²,Niswender Colleen M.¹²³,Jones Carrie K.¹²³,Brandon Nicholas J.⁴,Wood Michael W.⁴,Duggan Mark E.⁴,Conn P. Jeffrey¹²³,Bridges Thomas M.¹²,Lindsley Craig W.¹²^ORCID

Affiliation:

1. Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States

2. Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States

3. Vanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States

4. AstraZeneca Neuroscience, Innovative Medicines Biotech Unit, 141 Portland Street, Cambridge, Massachusetts 02139, United States

Funder

William K. Warren Foundation

National Institute of Mental Health

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.6b00461

Reference24 articles.

1. Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease

2. Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

3. Towards a muscarinic hypothesis of schizophrenia

4. The antipsychotic potential of muscarinic allosteric modulation

5. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A golden age of muscarinic acetylcholine receptor modulation in neurological diseases;Nature Reviews Drug Discovery;2024-08-14

2. Discovery of 2-Methyl-5-(1H-pyrazol-4-yl)pyridines and Related Heterocycles as Promising M₄ mAChR Positive Allosteric Modulators for the Treatment of Neurocognitive Disorders;Journal of Medicinal Chemistry;2024-07-18

3. Discovery of VU6008677: A Structurally Distinct Tricyclic M₄ Positive Allosteric Modulator with Improved CYP450 Profile;ACS Medicinal Chemistry Letters;2024-07-03

4. Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M₄ Muscarinic Acetylcholine Receptor;Journal of Medicinal Chemistry;2024-06-18

5. Preclinical Evaluation of Novel PET Probes for Dementia;Seminars in Nuclear Medicine;2023-09